Analysts Set West Pharmaceutical Services, Inc. (NYSE:WST) PT at $368.08

West Pharmaceutical Services, Inc. (NYSE:WST) has received an average rating of “Buy” from the fifteen ratings firms that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $368.0769.

A number of analysts have recently issued reports on WST shares. Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, August 7th. Zacks Research raised shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Citigroup upped their price objective on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Wolfe Research assumed coverage on shares of West Pharmaceutical Services in a research report on Monday, June 1st. They issued an “outperform” rating and a $375.00 target price for the company. Finally, BNP Paribas Exane started coverage on shares of West Pharmaceutical Services in a research note on Monday, July 13th. They set an “outperform” rating and a $447.00 target price for the company.

West Pharmaceutical Services Stock Performance

Shares of WST stock opened at $352.04 on Thursday. The company has a market capitalization of $24.78 billion, a price-to-earnings ratio of 45.08, a P/E/G ratio of 2.46 and a beta of 1.15. West Pharmaceutical Services has a 1-year low of $223.83 and a 1-year high of $386.00. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. The stock’s fifty day simple moving average is $345.18 and its 200-day simple moving average is $294.61.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The firm had revenue of $872.30 million during the quarter, compared to the consensus estimate of $839.98 million. During the same period in the prior year, the business earned $1.84 EPS. The business’s revenue for the quarter was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, sell-side analysts predict that West Pharmaceutical Services will post 8.94 earnings per share for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were issued a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 0.2%. The ex-dividend date was Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 11.27%.

Institutional Trading of West Pharmaceutical Services

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of West Pharmaceutical Services during the 2nd quarter valued at about $2,387,990,000. State Street Corp increased its holdings in West Pharmaceutical Services by 2.1% in the second quarter. State Street Corp now owns 3,271,866 shares of the medical instruments supplier’s stock worth $715,884,000 after buying an additional 68,330 shares during the last quarter. Artisan Partners Limited Partnership increased its holdings in West Pharmaceutical Services by 2.9% in the fourth quarter. Artisan Partners Limited Partnership now owns 2,850,401 shares of the medical instruments supplier’s stock worth $784,259,000 after buying an additional 79,481 shares during the last quarter. Bank of New York Mellon Corp bought a new position in West Pharmaceutical Services during the second quarter valued at approximately $733,733,000. Finally, Generation Investment Management LLP bought a new position in West Pharmaceutical Services during the second quarter valued at approximately $728,168,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.